Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation

American Journal of Transplantation

Volumn 9, Issue 9, 2009, Pages 2140-2149

  Van Laecke, S ^a   Van Biesen, W ^a   Verbeke, F ^a   De Bacquer, D ^b   Peeters, P ^a   Vanholder, R ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Calcineurin inhibitor agents; Magnesium; New onset diabetes mellitus; Renal transplant patients

Indexed keywords

ALBUMIN; ALFACALCIDOL; ANTIDIABETIC AGENT; BASILIXIMAB; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; DAPSONE; GANCICLOVIR; INSULIN; MAGNESIUM; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TRIACYLGLYCEROL; VALGANCICLOVIR;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BIOPSY PROVEN ACUTE REJECTION; BODY MASS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG DOSE REDUCTION; FEMALE; GRAFT REJECTION; HUMAN; HYPERGLYCEMIA; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEW ONSET DIABETES AFTER TRANSPLANTATION; PNEUMOCYSTIS PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

AGED; BODY MASS INDEX; CALCINEURIN; DIABETES MELLITUS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MAGNESIUM; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREVALENCE; RETROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS; TRIGLYCERIDES;

EID: 69149091953     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02752.x     Document Type: Article

References (42)

1. Miles AM, Sumrani N, Horowitz R et al. Diabetes mellitus after renal transplantation: As deleterious as non-transplant-associated diabetes? Transplantation 1998 65 : 380 384.
2. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003 3 : 178 185.
3. Mazali FC, Lalli CA, Alves-Filho G, Mazzali M. Posttransplant diabetes mellitus: Incidence and risk factors. Transplantation Proc 2008 40 : 764 766.
4. Araki M, Flechner SM, Ismail HR et al. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation 2006 81 : 335 341.
5. Maes BD, Kuypers D, Messiaen T et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: Analysis of incidence and risk factors. Transplantation 2001 72 : 1655 1661.
6. Pham PC, Pham PM, Pham SV, Miller JM, Pham PT. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007 2 : 366 373.
7. Nadler JL, Buchanan T, Natarajan R, Antonipillai I, Bergman R, Rude R. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 1993 21 (6 Pt 2 1024 1029.
8. He K, Liu K, Daviglus ML et al. Magnesium intake and incidence of metabolic syndrome among young adults. Circulation 2006 113 : 1675 1682.
9. Lopez-Ridaura R, Willett WC, Rimm EB et al. Magnesium intake and the risk of type 2 diabetes in men and women. Diabetes Care 2004 27 : 134 140.
10. Song Y, Manson JE, Buring JE, Liu S. Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. Diabetes Care 2004 27 : 59 65.
11. Rodríguez-Morán M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: A randomized double-blind controlled trial. Diabetes Care 2003 26 : 1147 1152.
12. Guerrero-Romero F, Tamez-Perez HE, González-González G et al. Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Diabetes Metab 2004 30 : 253 258.
13. Song Y, He K, Levitan EB, Manson JE, Liu S. Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: A meta-analysis of randomized double-blind controlled trials. Diabetes Med 2006 23 : 1050 1056.
14. Vannini SD, Mazzola BL, Rodoni L et al. Permanently reduced plasma ionized magnesium among renal transplant recipients on cyclosporine. Transpantl Int 1999 12 : 244 249.
15. Vicenti F, Friman S, Scheuermann E et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine vs. tacrolimus. Am J Transplant 2007 7 : 1506 1514.
16. Tamura K, Fujimura T, Tsutsumi T et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation 1995 59 : 1606 1613.
17. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008 31 (Suppl 1 S12 S54.
18. Pavlakis M, Goldfarb-Rumyantzev AS. Diabetes after transplantation and sirolimus: What's the connection? J Am Soc Nephrol 2008 19 : 1255 1256.
19. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007 357 : 2562 2575.
20. Büchler M, Caillard S, Barbier S et al. Sirolimus vs. cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007 7 : 2522 2531.
21. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005 16 : 3128 3135.
22. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002 23 : 201 229.
23. Mittelman SD, Bergman RN. Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin. Am J Physiol Endocrinol Metab 2000 279 : E630 E637.
24. Bussiere CT, Lakey JR, Shapiro AM, Korbutt CS. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 2006 49 : 2341 2349.
25. Kwon G, Marshall CA, Liu H, Pappan KL, Remedi MS, McDaniel ML. Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by KATP channels: Effects on cell cycle progression in rodent islets. J Biol Chem 2006 281 : 3261 3267.
26. Kao WH, Folsom AR, Nieto FJ, Mo JP, Watson RL, Brancati FL. Serum and dietary magnesium and the risk for type 2 diabetes mellitus: The atherosclerosis risk in communities study. Arch Int Med 1999 159 : 2151 2159.
27. Guerrero-Romero F, Rodríguez-Morán M. Low serum magnesium levels and metabolic syndrome. Acta Diabetol 2002 39 : 209 213.
28. Corica F, Corsonello A, Ientile R et al. Serum ionized magnesium levels in relation to metabolic syndrome in type 2 diabetic patients. J Am Coll Nutr 2006 25 : 210 215.
29. Mandon B, Siga E, Chabardes D, Firsov D, Roinel N, De Rouffignac C. Insulin stimulates Na+, Cl-, Ca2+ and Mg2+ transports in the TAL of mouse nephron: Cross-potentiation with AVP. Am J Physiol 1993 265 (3 Pt 2 F361 F369.
30. Balon TW, Gu JL, Tokuyama Y, Jasman AP, Nadler JL. Magnesium supplementation reduces development of diabetes in a rat model of spontaneous NIDDM. Am J Physiol 1995 269 (4 Pt 1 E745 E752.
31. Gueux E, Rayssiguier Y. The effect of magnesium deficiency on glucose stimulated insulin secretion in rats. Horm Metab Res 1983 15 : 594 597.
32. Dzúrik R, Stefiková K, Spustová V, Fetkovská N. The role of magnesium deficiency in insulin resistance: An in vitro study. J Hypertens Suppl 1991 9 : S312 S313.
33. Tonyai S, Motto C, Rayssiguer Y, Heaton FW. Erythrocyte membrane in magnesium deficiency. Am J Nutrit 1985 4 : A399.
34. Cosio FG, Kudva Y, van der Velde L et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005 67 : 2415 2421.
35. Alvarez A, Fernandez J, Porrini E et al. Carotid atheromatosis in non-diabetic renal transplant recipients: The role of prediabetic glucose homeostasis alterations. Transplantation 2007 84 : 870 875.
36. Porrini E, Moreno JM, Osuna A et al. Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: A prospective and multicenter study. Transplantation 2008 85 : 1133 1138.
37. Chadban S. New-onset diabetes after transplantation-should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients. Nephrol Dial Transplant 2008 23 : 1816 1818.
38. Porrini E, Delgado P, Alvarez A et al. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation. Nephrol Dial Transplant 2008 23 : 1436 1441.
39. Nijenhuis T, Hoenderop JG, Bindels RJ. Downregulation of Ca(2+) and Mg(2+) transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia. J Am Soc Nephrol 2004 15 : 549 557.
40. Ryzen E, Servis KL, DeRusso P, Kershaw A, Stephen T, Rude RK. Determination of intracellular free magnesium by nuclear magnetic resonance in human magnesium deficiency. J Am Coll Nutr 1989 8 : 580 587.
41. Guerrero-Romero F, Rascón-Pacheco RA, Rodríguez- Morán M, de la Peña JE, Wacher N. Hypomagnesaemia and risk for metabolic glucose disorders: A 10-year follow-up study. Eur J Clin Invest 2008 38 : 389 396.
42. Allegra A, Corica F, Ientile R et al. Plasma (total and ionized), erythrocyte and platelet magnesium levels in renal transplant recipients during cyclosporine and/or azathioprine treatment. Magnes Res 1998 11 : 11 18.